Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191412 · ClinicalTrials.gov registry record · Phase 2
A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00191412: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00191412 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00191412, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
Interventions
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
What the finished NCT00191412 record still lists
NCT00191412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00191412 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00191412 about?
NCT00191412 is a clinical study titled "A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver". This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
What is the current status of trial NCT00191412?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2005-01. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00191412?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00191412?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00191412's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia